Draft monograph: Dulaglutide — submissions

The analytical section is longer than the clinical assessment it accompanies

The respondent works on cardiometabolic outcomes and read the draft on Dulaglutide with that literature in view.

The respondent states that the analytical section occupies more of the monograph than the assessment of clinical effect, and that the proportions imply the Institute considers the analytical question the more important one.

The respondent proposes that the analytical material be moved to the standards series and referenced rather than reproduced.

The same concept is given three different names in one document

The respondent has read Dulaglutide in draft and makes a single submission.

The draft refers to the same quantity as a response rate, a responder proportion and a categorical outcome in different sections. The respondent, who works in health-technology assessment, states that a reader cannot tell whether the three refer to one thing or to three.

The respondent proposes that the glossary term be used at every occurrence and that the glossary entry be linked at first use in each section rather than only at first use in the document.

Local reactions are omitted from the adverse-event table because the trials reported them separately

This submission addresses the draft monograph on Dulaglutide. The respondent went through the document twice, once as a specialist and once as a reader arriving without the background.

Injection-site reactions are reported in the source trials in a table of their own and do not appear in the systemic adverse-event table the monograph reproduces. The result is that the most common adverse experience of a subcutaneously administered compound is absent from the monograph’s adverse-event section.

The respondent proposes that local reactions be carried in the same table as systemic events, with the reporting convention of the source trial recorded in a footnote.

Effect estimates are given without naming the comparator

Having reviewed the draft on Dulaglutide, the respondent makes a single submission, on the view that one point put clearly is more use to the secretariat than six put together.

Several estimates in the draft state an effect without stating what it was measured against. An estimate against placebo and an estimate against an active comparator are not the same quantity and the draft presents them in one column.

The respondent proposes that the comparator be part of every outcome row rather than a footnote, and that estimates against different comparators never share a column.

The population to which the headline estimate applies is not stated with the estimate

This submission concerns the draft on Dulaglutide. The respondent assesses incretin-class evidence for a national body and comments in a personal capacity.

The draft carries a headline effect estimate in the abstract without the eligibility criteria of the trials that produced it. The respondent states that the estimate applies to a trial population with specific age, comorbidity and baseline criteria, and that a reader will apply it to whoever is in front of them.

The respondent proposes a one-line population statement adjacent to every headline estimate.

Adverse event frequencies are given without the denominator or the exposure period

The respondent submits on the draft monograph for Dulaglutide. The observation arises from teaching the material rather than from prescribing it.

The draft reports adverse event frequencies as percentages. The respondent states that a percentage without a denominator and without an exposure period cannot be compared with any other figure, including the corresponding figure in the comparator arm.

The respondent proposes that every frequency carry the number of participants and the exposure period over which it was observed.

The respondent notes submission 001 above and does not repeat the ground it covers.

Nothing is said about impaired renal or hepatic clearance

The draft on Dulaglutide was read in full. The respondent notes at the outset that this class has an unusually deep randomised evidence base, and that a monograph on it is fairly judged against a higher standard than one on a compound with none.

The pharmacokinetic section gives clearance and half-life in healthy volunteers or in the trial population. It does not say whether either has been characterised in impaired renal or hepatic function, which is the question a clinician reaches the section with.

The respondent proposes that the pharmacokinetic section state, for each compound, whether a dedicated study in impaired function exists, and where none does, say so rather than leaving the field out.

Mechanistic claims for a peptide fragment are carried without evidence that the fragment acts as described

The draft on Dulaglutide is a substantial document and the respondent has confined this submission to one matter.

The respondent states that the draft repeats a mechanistic account originating in supply documentation rather than in the primary literature, and that the account attributes activity to a fragment on the basis of the activity of the parent molecule.

The respondent proposes that any mechanistic claim be traceable to a primary source and removed where it is not.

Open-label extension data are presented alongside randomised data without distinction

The respondent has read the draft monograph on Dulaglutide against a caseload in which incretin analogues are prescribed daily.

Long-term figures in the clinical section come from open-label extensions in which every participant received the active compound and those who did not tolerate it had already withdrawn. They are printed in the same table as randomised comparisons and in the same typeface.

The respondent proposes that extension data be presented in a separate table, or at minimum in a separately labelled block, and that the surviving-population problem be stated once where it arises.

This submission should be read alongside submission 004, which arises on the same draft.

Absence of evidence is presented in a form a reader will take as negative evidence

The respondent read the draft on Dulaglutide alongside the approved labelling for the class, and submits on one matter arising.

Where the Institute has identified no study, the draft states that no evidence was found. In several places that sentence sits immediately after a paragraph describing an adverse outcome, and the juxtaposition invites the reading that the compound was studied and found wanting.

The respondent proposes a standing formulation, used identically wherever the situation arises, distinguishing an outcome that was studied and not demonstrated from an outcome that has not been studied at all.

The pharmacokinetic section does not connect half-life to the dosing schedule

This is a submission on the draft covering Dulaglutide, from a respondent whose work is with the people taking compounds of this class rather than with the trials that produced them.

The draft reports a half-life and, separately, a dosing interval. The respondent, a clinical pharmacologist, states that the relationship between the two is what determines accumulation and time to steady state, and that the monograph leaves the reader to derive it.

The respondent proposes that time to steady state be stated explicitly, with the assumption from which it was derived.